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206 Abstract (250 words)
207 Background: Whether active therapy with β-lactam/β-lactamase inhibitors (BLBLI) is as affective as 
208 carbapenems for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream 
209 infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTR) remains 
210 unclear.
211 Methods: We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to 
212 October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any 
213 cause) at days 7 and 30 from ESBL-E BSI onset were primary and secondary study outcomes, 
214 respectively.
215 Results: Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of 
216 patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) 
217 and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure 
218 at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 
219 1.35-2.17) and lymphocyte count ≤500 cells/μL at presentation (aOR: 3.16; 95% CI: 1.42-7.06) 
220 predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) 
221 was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-
222 tazobactam). Propensity score-adjusted models revealed no significant impact of the choice of active 
223 therapy (carbapenem-containing versus any other regimen, BLBLI- versus carbapenem-based 
224 monotherapy) within the first 72 hours on any of the study outcomes. 
225 Conclusions: Our data suggest that active therapy based on BLBLI may be as effective as 
226 carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. 
227 Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov 
228 identifier: NCT02852902).
229
230 Keywords: kidney transplantation; extended-spectrum β-lactamase-producing Enterobacterales 
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233 INTRODUCTION
234 Bloodstream infections (BSI) represent a common complication after solid organ transplantation 
235 (SOT), with an incidence higher than that expected in the general population1. Urinary tract infection 
236 (UTI) is the most common source of BSI in kidney transplant recipients (KTR)2–4, mainly due to the 
237 combined impact of invasive procedures on the urinary tract and underlying immunosuppression2,5. 
238 The increasing prevalence of infections due to multidrug-resistant (MDR) gram-negative bacilli, such 
239 as extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E), is of particular 
240 concern in the SOT setting6–9. Approximately 10% of KTR will develop an UTI caused by ESBL-E within 
241 the first year10, and these patients face a three times higher risk of recurrence compared to those 
242 infected with non-MDR bacteria10,11.
243 The management of infections caused by ESBL-E remains challenging, with limited antimicrobials 
244 available and scarce supporting evidence. Carbapenems have been considered as the front-line 
245 therapy both in the general population12 and in immunocompromised patients, including KTR13. 
246 Observational studies conducted in the general population —such as the multinational INCREMENT 
247 cohort (ClinicalTrials.gov identifier: NCT01764490)— have shown that, for organisms showing in 
248 vitro susceptibility, β-lactam/β-lactamase inhibitors (BLBLI) may be a good alternative to 
249 carbapenems for the treatment of BSI due to ESBL-E, particularly among non-critically ill patients 
250 with UTI14–17. On the contrary, other studies, including a recently published randomized trial, have 
251 reported a difference in mortality favoring carbapenems18–20. Interpretation of previous studies is 
252 further complicated due to the lower reliability and reproducibility of in vitro susceptibility testing to 
253 piperacillin-tazobactam as compared to carbapenems when gradient methods such as E-test are 
254 used21. Whether these findings can be extrapolated to the SOT population remains to be assessed. 
255 The aim of the present study was to compare the impact of therapeutic regimens based on 
256 carbapenems versus BLBLI on the clinical outcome in a large multinational cohort of KTR with ESBL-E 
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258 MATERIALS AND METHODS
259 Study population and setting
260 The INCREMENT-SOT project (ClinicalTrials.gov identifier NCT02852902) comprised a retrospective 
261 international cohort of SOT recipients diagnosed with clinically significant (i.e. meeting criteria for 
262 systemic inflammatory response syndrome) BSI due to ESBL-E or carbapenemase-producing 
263 Enterobacterales admitted to 40 tertiary hospitals in 16 countries from January 2004 to October 
264 2016. For the present analysis, KTR with monomicrobial ESBL-E BSI secondary to UTI were eligible. 
265 Patient data were collected at each site by review of microbiology reports and patients’ charts until 
266 day 30 after incident blood cultures (BCs) were taken. Exclusion criteria were key missing data 
267 regarding therapeutic regimens and/or outcomes, death earlier than 24 hours after the index date 
268 (i.e. that of BSI onset), and the administration of active therapy for at least 2 days prior to BC 
269 sampling. The study protocol was approved by the Spanish Agency of Medicines (code FIB-COL-
270 2015-01) and by the Ethics Committee of the Hospital Universitario Reina Sofía (Act 243, code 2907), 
271 which waived the need to obtain written informed consent. Approval was also gained at 
272 participating centers according to local requirements.
273 Study outcomes and definitions
274 The primary study outcome was therapeutic failure, defined as the lack of cure or clinical 
275 improvement (i.e. persistence or worsening of fever, leukocytosis or other signs of infection, and/or 
276 persistently positive BC for the same microorganism) and/or death from any cause, at day 7 from 
277 the onset of BSI. Therapeutic failure at day 30 was considered as secondary outcome. The main 
278 explanatory variable was the type of active therapy (according to the categories defined below) 
279 administered within the first 72 hours from BSI onset. Sensitivity analyses were also performed 
280 based on the regimen used during the first 24 hours and 7 days. The tested hypothesis (BLBLI are not 
281 associated with worse outcomes than carbapenem-containing regimens after controlling for 
282 potential confounders) was specified a priori in the study protocol. Due to the exploratory nature of 
283 the study and the expected low proportion of patients treated with BLBLI across participating 
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285 was performed. In addition, the statistical analysis was not formally modelled on a non-inferiority 
286 assumption.
287 Episodes of ESBL-E BSI were considered hospital-acquired if symptoms started beyond the first 48 
288 hours from hospital admission or within 48 hours from a previous hospital discharge. 
289 Enterobacterales were identified using standard microbiological techniques at each centre. ESBL 
290 production was screened in all isolates with diminished susceptibility to third-generation 
291 cephalosporins —a key phenotypic property of ESBL enzymes— and confirmed by standard 
292 methods22. Susceptibility was studied using automated systems or disk diffusion and interpreted 
293 according to the guidelines (Clinical and Laboratory Standards Institute [CLSI] or European 
294 Committee on Antimicrobial Susceptibility Testing [EUCAST]) applied at each centre23,24. Isolates 
295 were considered to be ESBL producers if at least one phenotypic confirmatory test was positive 
296 according to the corresponding CLSI or EUCAST criteria applicable at the time of testing, or if they 
297 had been characterized by PCR and DNA sequencing using established methods.
298 Active therapy was defined as administration of at least one antimicrobial agent to which the isolate 
299 showed susceptibility in vitro, at the standard dose and frequency12. Specifically, standard 
300 intravenous dosing regimens for the most common antimicrobials administered were as follows: 
301 piperacillin-tazobactam, 3/0.375 g to 4/0.5 g every 6-8 hours; meropenem, 1-2 g every 8 hours; 
302 ertapenem, 1 g every 24 hours; and imipenem-cilastatin, 500/500 mg to 1/1 g every 6-8 hours. All 
303 doses were adjusted to renal function. The therapy was considered to be inactive if the isolate was 
304 non-susceptible to the agent(s) administered or the dosing was inappropriate. Monotherapy was 
305 defined as the administration of a single active drug for at least 48 hours (except for patients that 
306 died in less than 48 hours, who were included if they received at least one complete day of therapy). 
307 The definition criteria for combination antibiotic therapy (i.e. simultaneous administration of two or 
308 more active drugs) varied according to the time elapsed since the initiation of treatment, in order to 
309 account for changes in antimicrobial therapy during the course of BSI (from empirical to targeted 
310 therapy). For the first 24 or 72 hours from the onset of BSI, combination therapy was defined as the 
311 administration of two or more active antimicrobial agents for at least 24 hours. For therapy 
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313 at least 72 hours. Source control included at least one of the following measures: surgical 
314 debridement (e.g. laparotomy for organ/space surgical site infection), non-surgical debridement 
315 (e.g. imaging-guided drainage of perinephric abscess or infected kidney cyst), and/or removal or 
316 replacement of urinary catheter. To avoid confounding by indication bias, only those source control 
317 procedures performed before the time of outcome assessment (i.e. days 7 and 30 for the primary 
318 and secondary outcomes, respectively) were taken into account. Severity of infection and 
319 comorbidity burden were assessed by means of the Pitt bacteremia score25, the age-adjusted 
320 Charlson Comorbidity Index (CCI)26 and the McCabe score27. The diagnosis of cytomegalovirus (CMV) 
321 infection required the presence of laboratory-confirmed CMV replication by either pp65 
322 antigenemia assay or PCR-based nucleic acid amplification testing. CMV disease was defined as 
323 evidence of CMV replication with attributable symptoms28.
324 Statistical analysis
325 Continuous variables were presented as the mean ± standard deviation (SD) or the median with 
326 interquartile range (IQR). Categorical data were expressed as absolute and relative frequencies. The 
327 χ2 test or Fisher’s exact test were used to compare categorical variables, as appropriate. The 
328 Student’s t-test or Mann-Whitney U test were applied for continuous variables. Univariate and 
329 multivariable logistic regression models were applied to identify factors predicting therapeutic 
330 failure. For analysis of therapeutic failure at days 7 and 30 (primary and secondary outcomes), we 
331 explored the impact of the antibiotic regimen administered within the first 72 hours from the onset 
332 of BSI. Further sensitivity analyses were performed according to the regimen used during the first 24 
333 hours (for primary and secondary outcomes) and 7 days (for the secondary outcome only). At each 
334 of these windows, therapeutic regimens were classified into one of the following mutually exclusive 
335 categories: active versus inactive therapy; combination therapy versus monotherapy; carbapenem-
336 containing versus other active regimens; and carbapenem versus BLBLI monotherapy. Absolute risk 
337 differences with 95% confidence intervals (CIs) were determined with the allegedly more effective 
338 regimen (i.e. combination therapy, carbapenem-containing regimen, and carbapenem 
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340 Associations were given as odds ratios (ORs) and 95% CIs. Multicollinearity among explanatory 
341 variables was analyzed using the variance inflation factor (VIF). The Hosmer-Lemeshow test was 
342 used to assess the goodness-of-fit of the models. Thirty-day survival curves were plotted by the 
343 Kaplan-Meier method and differences related to therapeutic regimens were compared with the log-
344 rank test.
345 To partially overcome the limitation posed by the non-randomized design of the study, we 
346 calculated the propensity scores (PS) for receiving either carbapenem-containing therapy (versus 
347 any other active regimen) or BLBLI-based (versus carbapenem-based) monotherapy, within the first 
348 72 hours and given the patient’s baseline characteristics and the clinical features at BSI presentation. 
349 Both scores were estimated by means of backward stepwise logistic regression models including 
350 variables with P-values <0.1 in the univariate analysis (Tables S1 and S2), and the fit of the resulting 
351 models were assessed by means of the area under the receiving operator characteristics curve 
352 (auROC). PS were entered as a covariate in multivariable models to adjust for potential confounding 
353 by factors influencing the choice of therapy.
354 Statistical analysis was performed with SPSS version 20.0 (IBM Corp., Armonk, NY) and graphs were 
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356 RESULTS
357 Characteristics of the study population
358 Overall, 306 episodes of ESBL-E BSI occurring in 306 KTR were included from 30 centers in 14 
359 countries. The clinical and microbiological features are shown in Table 1. The median interval from 
360 transplantation to BSI onset was 119 days, and 23.2% of the episodes occurred within the first 
361 month. The median length of stay was 16 days (9 – 33.5). Most patients were receiving triple 
362 maintenance immunosuppression consisting of corticosteroids, tacrolimus and mycophenolic acid or 
363 mycophenolate mofetil. Regarding the ESBL-E identified, Escherichia coli (62.1%) and Klebsiella spp. 
364 (35.0%) accounted for the majority of cases.
365 Therapeutic failure at days 7 and 30 (primary and secondary outcomes) occurred in 8.2% (25/306) 
366 and 13.4% (41/306) of patients. All-cause mortality rates at days 7 and 30 were 1.0% (3/306) and 
367 2.9% (9/306), respectively. All but one death were considered attributable to ESBL-E BSI. The rates of 
368 cure and clinical improvement were 2.6% (8/206) and 89.2% (273/306) by day 7, and 77.5% 
369 (237/306) and 9.2% (28/306) by day 30, respectively. 
370 The therapeutic regimens given at different time intervals are detailed in Table 2. Most patients 
371 received active therapy with carbapenem monotherapy (144 [47.1%] for the first 24 hours, 210 
372 [68.6%] %] for the first 72 hours, and 237 [77.5%] for the first 7 days from BSI onset), whereas BLBLI 
373 monotherapy (mostly piperacillin-tazobactam) was chosen in about 10% of cases. Piperacillin-
374 tazobactam was most commonly administered at doses of 4/0.5 g every 8 hours (46.7% [14/30]) and 
375 2/0.25 g every 8 hours (20.0% [6/30]). The use of combination antibiotic therapy was anecdotal. 
376 Twenty-one patients (6.8%) received during the first 72 hours an antibiotic that lacked in vitro 
377 activity against the isolate, which mainly included second- or third-generation cephalosporins (10 
378 patients [47.6%]), piperacillin-tazobactam (8 patients [38.1%]) or quinolones (2 patients [9.5%]). 
379 Within the subgroup pf patients that received monotherapy during the first 72 hours from BSI onset, 
380 5.0% (13/261) were subsequently transitioned to a second active antibiotic.
381 Risk factors for therapeutic failure
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383 outcome) are shown in Table 3. At the univariate level, recipient gender, time interval from 
384 transplantation to BSI onset, use of trimethoprim-sulfamethoxazole prophylaxis, presence of urinary 
385 stenosis, hospital-acquired infection, acute rejection within the prior month, Pitt bacteremia score, 
386 and the degree of sepsis severity were associated with this outcome. Since the Pitt score and the 
387 presence of septic shock exhibited significant multicollinearity (VIF values >1.5), only the former 
388 variable was included into the logistic regression model. The presence of hospital-acquired BSI (OR: 
389 4.10; 95% CI: 1.50 – 11.20; P-value = 0.006) and the Pitt bacteremia score at BSI onset (OR [per one-
390 point increase]: aOR: 1.47; 95% CI: 1.21 – 1.77; P-value <0.0001) remained as independent 
391 predictors for therapeutic failure at day 7. 
392 Age-adjusted CCI (OR [per one-point increase]: 1.25; 95% CI: 1.05 – 1.48; P-value = 0.010), Pitt score 
393 (OR [per one-point increase]: 1.72; 95% CI: 1.35 – 2.17; P-value <0.0001) and an absolute 
394 lymphocyte count ≤500 cells/μL at BSI onset (OR: 3.16; 95% CI: 1.42 – 7.06; P-value = 0.005) were 
395 independent predictors for therapeutic failure at day 30 (Table 4). There were no significant 
396 differences in 30-day survival between patients receiving or not receiving active therapy within the 
397 first 24 (98.3% versus 95.3%, respectively; log-rank test P-value = 0.365) or 72 hours (100.0% versus 
398 95.9%; log-rank test P-value = 0.293) from the onset of BSI.
399 Impact of different therapeutic regimes on study outcomes
400 The impact on study outcomes of different regimens was next investigated within the subgroup of 
401 participants that received active therapy. First, we compared the incidence of therapeutic failure at 
402 day 7 (primary outcome) in patients receiving combination therapy versus monotherapy during the 
403 first 72 hours from the onset of BSI, with no significant differences found between both groups 
404 (8.3% [1/12] versus 8.4% [22/261], respectively; risk difference: 0.06%; 95% CI: -0.15 – 0.16; 
405 unadjusted OR [uOR]: 0.99; 95% CI: 0.12 – 8.01; P-value = 0.991) (Figure 1a). There were no 
406 significant differences in the occurrence of therapeutic failure at day 30 (secondary outcome) either 
407 (16.7% [2/12] versus 13.0% [34/261]; risk difference: -3.63%; 95% CI: -0.23 – 0.16; uOR: 1.34; 95% CI: 
408 0.28 – 6.36; P-value = 0.717) (Figure 1b). Next, we evaluated the impact of using a carbapenem-
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410 differences were observed, either at day 7 (8.7% [19/219] versus 7.4% [4/54]; risk difference: -
411 1.27%; 95% CI: -0.09 – 0.07; uOR: 1.18; 95% CI: 0.39 – 3.65; P-value = 0.764) (Figure 2a) or day 30 
412 (13.7% [30/219] versus 11.1% [6/54]; risk difference: -2.59; 95% CI: -0.13 – 0.07; uOR: 1.27; 95% CI: 
413 0.50 – 3.23; P-value = 0.615) (Figure 2b). Finally, we compared the risk of therapeutic failure 
414 between patients treated with carbapenem monotherapy versus BLBLI monotherapy. Once again, 
415 we observed no significant differences at day 7 (9.0% [19/210] versus 3.0% [1/33]; risk difference: -
416 6.01%; 95% CI: -0.16 – 0.04; uOR: 3.18; 95% CI: 0.41 – 24.62; P-value = 0.267) (Figure 2a) or day 30 
417 (13.8% [29/210] versus 9.1% [3/33]; risk difference: -4.72%; 95% CI: -0.17 – 0.08; uOR: 1.60; 95% CI: 
418 0.46 – 5.59; P-value = 0.459) (Figure 2b) between both therapeutic modalities. In addition, there 
419 were no significant differences in hospital stay between any of these therapeutic regimens (Table 
420 S3).
421 Propensity score-adjusted analysis
422 Next, we applied a PS-based approach to investigate whether the therapeutic regimen administered 
423 within the first 72 hours from BSI onset influenced study outcomes. The following variables were 
424 included in the PS for the use of a carbapenem-containing regimen: geographical area (Europe or 
425 North America versus other sites), simultaneous kidney-pancreas transplantation, certain pre-
426 transplant chronic conditions (diabetes, liver disease, congestive heart failure and chronic 
427 pulmonary disease), CMV disease within the prior month, and presence of a rapidly or ultimately 
428 fatal disease according to the McCabe score (Table S1). The auROC of the resulting PS was 0.738 
429 (95% CI: 0.664 – 0.812). The risk of therapeutic failure at day 7 (PS-adjusted OR: 4.66; 95% CI: 0.58 – 
430 37.28; P-value = 0.147) or at day 30 (PS-adjusted OR: 2.13; 95% CI: 0.55 – 8.20; P-value = 0.274) were 
431 not found to be significantly affected by the use of a carbapenem-containing regimen versus any 
432 other active regimen. In addition, we further adjusted by the degree of sepsis severity (Pitt score and 
433 presence of septic shock) and comorbidity burden in different regression models, since the relatively 
434 low number of patients suffering from therapeutic failure at either point was insufficient to perform 
435 a single multivariable analysis without incurring in model overfitting. None of these adjustments 
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437 alternative regimen (Figure S1).
438 This methodological approach was also applied to compare the use of BLBLI versus carbapenem 
439 within the subgroup of patients treated with monotherapy in the first 72 hours from BSI onset. The 
440 variables included in the PS for the use of carbapenem-based monotherapy as compared to BLBLI-
441 based monotherapy were: geographical area (Europe or North America versus other study sites), 
442 pre-transplant chronic conditions (congestive heart failure and chronic pulmonary disease), 
443 presence of a rapidly or ultimately fatal disease according to the McCabe score, and receipt of active 
444 therapy within the first 24 hours (Table S2). The auROC of the score was 0.794 (95% CI: 0.719 – 
445 0.869). Again, neither the risk of therapeutic failure at day 7 (PS-adjusted OR: 4.36; 95% CI: 0.51 – 
446 37.38; P-value = 0.179) or day 30 (PS-adjusted OR: 2.59; 95% CI: 0.66 – 10.21; P-value = 0.175) 
447 appeared to be influenced by the choice of carbapenem-based versus BLBLI-based monotherapy 
448 (Figure S2).
449 Sensitivity analysis
450 Finally, to evaluate the consistency of these findings, we investigated the impact of therapy 
451 administered during time periods other than the 72-hour window. There were no significant 
452 differences in the incidence of 7-day and 30-day therapeutic failure among different therapeutic 
453 regimens administered within the first 24 hours from BSI (Figures S3 and S4, Table S4). No 
454 significant differences were found in 30-day therapeutic failure according to the type of therapy 
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456 DISCUSSION
457 In the present study we were not able to detect significant differences in the risk of therapeutic 
458 failure (lack of cure or clinical improvement and/or death from any cause) among KTR with ESBL-E 
459 BSI secondary to UTI that were treated with carbapenem- or BLBLI-based regimens. Absolute risk 
460 differences observed were small (ranging from -6.01% to 0.06%) and of questionable relevance from 
461 a clinical perspective. Although current consensus statements favor BLBLI-based regimens for non-
462 severe ESBL infections29,30, such recommendations are supported by limited data. Our research 
463 would reinforce previous studies suggesting that BLBLI monotherapy may be as effective as a 
464 carbapenem to treat ESBL-E BSI, particularly for low-inoculum infections in non-critically ill 
465 patients14–17.
466 Due to the very low number of KTR within the BLBLI group that received amoxicillin-clavulanic acid 
467 (n = 2), our results are mostly applicable to piperacillin-tazobactam, in line with other studies 
468 performed in the non-transplant population16,17. Whether both BLBLIs are equally effective for 
469 treating ESBL-E remains debatable, although a potential “inoculum effect” has been proposed for 
470 piperacillin-tazobactam but not amoxicillin-clavulanic acid31. In addition, variations have been 
471 reported in the rates of susceptibility to piperacillin–tazobactam according to the specific ESBL 
472 enzyme involved, with higher activity for CTX-M-14-like enzymes as compared to other β-lactamases 
473 (such as CTX-M-15-like, CMY-like, OXA-1 or SHV enzymes)32. It should be noted that the CLSI and 
474 EUCAST guidelines differ in the interpretative criteria for categorizing an isolate as susceptible to 
475 piperacillin-tazobactam, with minimum inhibitory concentration (MIC) breakpoints set at ≤16 mg/L 
476 and ≤8 mg/L, respectively. Given the retrospective design of the study, such a discrepancy 
477 complicates data aggregation across centers. Indeed, if we focused on episodes treated with 
478 piperacillin-tazobactam monotherapy during the first 72 hours, 67.7% (21/31) and 32.3% (10/31) of 
479 the isolates had been tested by the CLSI and EUCAST methods.
480 To our knowledge, this is the first study to compare the efficacy of carbapenems and BLBLI for ESBL-
481 E BSI in the specific setting of SOT. Immunocompromised individuals were included in a systematic 
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483 treated with carbapenems or other regimens14. Nonetheless, most of them were diagnosed with 
484 malignancy and neutropenia, with only a low number of SOT recipients33. In line with these findings, 
485 a recent international study in neutropenic hematological patients with ESBL-E BSI also failed to 
486 demonstrate differences between carbapenems and BLBLI34.
487 In contrast with our results and most of the previously reported studies, results from a multicenter, 
488 open-label, randomized non-inferiority trial of piperacillin-tazobactam versus meropenem for the 
489 definitive treatment of BSI due to ceftriaxone-resistant E. coli or K. pneumoniae did not support the 
490 use of BLBLI as a carbapenem-sparing option20. In contrast to the present study, about one third of 
491 the participants in the MERINO trial had non-urinary sources, and the risk difference for 30-day 
492 mortality in this subgroup was sensibly higher than that observed among patients with BSI from 
493 urinary source (14.1% versus 3.7%, respectively). Previous studies have demonstrated poorer 
494 outcomes in infections from non-urinary sources treated with piperacillin-tazobactam-based 
495 regimens35,36.
496 The absence of demonstrable differences in the rates of therapeutic failure at days 7 and 30 among 
497 patients receiving BLIBL versus carbapenems must be interpreted with particular caution, given the 
498 low number of patients treated with BLBLI and the subsequent risk of inadequate power to reject 
499 the null hypothesis. Alternative carbapenem-sparing active regimens other than BLBLI were used in 
500 a small proportion of patients, which precludes conclusions about their potential efficacy for the 
501 treatment of post-transplant ESBL-E BSI of urinary origin. The lack of a priori sample size calculation 
502 renders our study hypothesis-generating rather than confirmatory. In addition, we found no 
503 differences in the rates of therapeutic failure between patients treated with combination therapy or 
504 monotherapy, regardless of the time elapsed from the onset of BSI to the initiation of an in vitro 
505 active agent. 
506 The low mortality rates observed (1.0% at day 7 and 2.9% at day 30) were consistent with those 
507 previously published among KTR, which ranged from 2.5% to 11%36,37, and would have contributed 
508 to the quite unexpected lack of apparent impact in terms of worse outcomes of not receiving active 
509 therapy. The improved outcomes reported for BSI from urinary source may be explained by the 
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511 in the urinary tract. Although the development of septic shock represents a major predictor of 
512 mortality36, Kalil et al. showed that mortality was actually lower in SOT recipients with bacteremic 
513 sepsis compared with non-transplant patients, suggesting that post-transplant immunosuppression 
514 may provide a survival advantage through modulation of the inflammatory response38. On the other 
515 hand, the overall favorable outcomes found in our study may reflect the occurrence of a less severe 
516 infection, consistent with the low age-adjusted CCI (median of 4) and Pitt bacteremia (median of 0) 
517 score values, and the small proportion of patients with rapidly fatal disease (4.9%).
518 In the multivariable analysis, hospital-acquired infection and Pitt score were associated with an 
519 increased odds of therapeutic failure at day 7. On the other hand, age-adjusted CCI, Pitt score and 
520 the presence of lymphopenia (≤500 cells/μL) at presentation were associated with therapeutic 
521 failure at day 30. Surprisingly, despite the high rate of inadequate (non-active) initial empiric 
522 antimicrobial therapy within the first 24 and 72 hours (37.9% and 10.8%, respectively), this variable 
523 was not associated with a worse outcome in either univariate or multivariable models. Previous 
524 studies have also reported high rates of inadequate initial antimicrobial therapy to treat ESBL-E BSI 
525 in the overall population39–41, which may reach up to 60% in studies targeting the SOT population6. 
526 Some previous studies reported that, following multivariate adjustment, inappropriate initial empiric 
527 therapy was not associated with increased mortality after SOT6, although inadequately treated UTI 
528 episodes exerted a deleterious impact on graft function and patient survival among KTR3,5. Again, 
529 such a low mortality rate may be related to the lower inflammatory response in these patients 
530 compared to non-transplant patients. Unfortunately, we lack data on the medium- and long-term 
531 evolution of renal graft function between patients receiving or not adequate therapy, although no 
532 significant differences were found in the overall length of stay (which may serve as a proxy for the 
533 development of acute kidney injury or the requirement of renal replacement therapy during the 
534 incident hospitalization).
535 Carbapenem monotherapy (primarily meropenem) was the most frequent active therapy used, 
536 followed by BLBLI (mostly piperacillin-tazobactam). To overcome the limitation posed by the non-
537 randomized retrospective design, PS-adjusted analyses for receiving the front-line and intuitively 
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539 “alternative” less potent regimen were carried out. The PS-adjusted risk of therapeutic failure at 
540 days 7 and 30 did not significantly differ between patients treated with a carbapenem-containing 
541 regimen within the first 72 hours and those receiving any other active regimens. No impact was 
542 demonstrated for the choice of BLBLI-based versus carbapenem-based monotherapy either, 
543 although these subgroup analyses must be taken with particular caution due to the small sample 
544 sizes. In addition, a small proportion of patients were transitioned to a different active antibiotic 
545 beyond the first 72 hours, posing a potential risk of misclassification bias.
546 This study has several limitations. Firstly and most importantly, statistical power may be insufficient 
547 given the low number of patients that received some specific regimens (such as BLBLI or 
548 combination therapy) and the low rates of therapeutic failure and death, as discussed above. In 
549 other words, only large absolute risk differences between therapeutic groups would have been 
550 detected with the present sample size. Secondly, we have included cases of ESBL-E BSI based only on 
551 the phenotypic profile of resistance. Although ceftriaxone non-susceptibility is often used as a simple 
552 surrogate marker for ESBL production, not all Enterobacterales with a ceftriaxone MIC greater than 1 
553 mg/L are ESBL producers42. Thirdly, we were not able to examine the potential impact of the MICs of 
554 the reported antibiotic agents on therapeutic failure, since these data were not always provided by 
555 the participating centers; rather, we assumed this limitation and used the informed category of 
556 susceptibility or resistance as reported by local investigators. Previous studies have shown that 
557 infections caused by Enterobacterales with higher MIC values for piperacillin-tazobactam have an 
558 increased risk for non-favorable outcome compared to isolates with lower MIC values42,43. Fourthly, 
559 while we considered data regarding BLBLI dose, frequency of administration, and duration of 
560 treatment in order to assess the adequacy of therapy, the low number of patients precluded any 
561 further analyses regarding the potential impact of the different treatment schemes used. High-dose 
562 and/or continuous infusion regimens have been associated with higher probability of therapeutic 
563 success15,44. Fifthly, no specific information on the differential impact of the therapeutic regimens 
564 analyzed on graft function was collected. Finally, potential overfitting of multivariable models (with 
565 associated instability) cannot be ruled out due to the relatively low number of patients, particularly 
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567 How the present findings can inform decision-making process in clinical practice? While the 
568 empirical use of a carbapenem-containing regimen should be always considered in a given recipient 
569 with sepsis from a presumed urinary source due to the high proportion of infections due to ESBL-E in 
570 this population (estimated at 33% in the above-mentioned meta-analysis, with large geographical 
571 variations10), early de-escalation to an alternative carbapenem-sparing regimen may be safely 
572 implemented once in vitro susceptibility has been demonstrated, with preference given to 
573 piperacillin-tazobactam monotherapy. On the other hand, the switch to a carbapenem before 
574 antimicrobial susceptibility testing become available would not be mandatory for those recipients 
575 that have been already initiated on BLBLI and are experiencing good clinical evolution during the first 
576 hours from BSI onset. This strategy would contribute to minimize the spread of carbapenem-
577 resistant Enterobacterales in the transplant setting. The ongoing PETERPEN (NCT03671967) and 
578 MERINO-3 (NCT04238390) trials, which are exploring the role of piperacillin-tazobactam and 
579 ceftolozane-tazobactam for infections due to third-generation cephalosporin-resistant 
580 Enterobacterales in non-transplant patients, will hopefully shed light on this question.
581 In conclusion, although preliminary in nature, our results would support previous evidence from 
582 non-immunocompromised patients suggesting that BLBLI (namely piperacillin-tazobactam) may be 
583 as effective as carbapenem-containing regimens to treat ESBL-E BSI secondary to UTI in KTR, 
584 provided the isolate is susceptible in vitro. The present findings can inform the design of pragmatic, 
585 non-inferiority randomized clinical trials confirm the role of carbapenem-sparing approaches in the 
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729 TABLES
730 TABLE 1. Clinical characteristics of the study cohort.
Variable (n = 306)
Patient-related variables
Age, years [mean ± SD] 56.6 ± 13.9
Male gender [n (%)] 163 (53.3)
Geographic area [n (%)]
Europe 190 (62.1)
Asia 56 (18.3)
South America 18 (5.9)
North America 17 (5.6)
Israel 25 (8.2)
McCabe score [n (%)]
Non-fatal 230 (75.2)
Ultimately fatal 61 (19.9)
Rapidly fatal 15 (4.9)
Age-adjusted CCI [median (IQR)] 4 (3  6)
Major pre-transplant comorbidities [n (%)]
Diabetes 152 (49.7)
Coronary heart disease 45 (14.7)
Congestive heart failure 37 (12.1)
Liver disease 31 (10.1)











This article is protected by copyright. All rights reserved
Time from transplantation to BSI onset, days [median 
(IQR)]
119 (35.3  
1.378)
BSI within the first post-transplant month [n (%)] 71 (23.2)
Simultaneous kidney-pancreas transplantation [n (%)] 5 (1.6)
Induction therapy [n (%)]
Basiliximab 110 (35.9)
Antithymocyte globulin 82 (26.8)




Mycophenolic acid/mycophenolate mofetil 244 (79.7)
Azathioprine 22 (7.2)
mTOR inhibitor 26 (8.5)
TMP/SMX prophylaxis within the prior month [n (%)] 163 (53.3)
Urinary stenosis at BSI onset [n (%)] 55 (18.0)
ICU admission within the prior month [n (%)] 37 (12.1)
Dialysis within the prior month [n (%)] 65 (21.2)
CMV infection within the prior month [n (%)] 31 (10.1)
CMV disease within the prior month [n (%)] 15 (4.9)
Acute graft rejection within the prior month [n (%)] 30 (9.8)
BSI episode-related variables
Hospital-acquired BSI [n (%)] 127 (41.5)
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Hemodynamic severity [n (%)]a
Severe sepsis 36 (12.6)
Septic shock 13 (4.5)
Lymphocyte count at presentation ≤500 cells/μL [n (%)]b 117 (39.9)
Microbiological results [n (%)]
Escherichia coli 190 (62.1)
Klebsiella spp. 107 (35.0)
Enterobacter spp. 4 (1.3)
Other 5 (1.6)
Treatment-related variables and outcomes
BSI source control [n (%)] 113 (36.9)
Surgical debridement 26 (8.5)
Non-surgical debridement 44 (14.4)
Removal/replacement of urinary catheter 67 (21.9)
Time to BSI source control, days [median (IQR)]c 3 (0  9)
Overall duration of therapy, days [median (IQR)]d 14 (12  21)
Duration of active therapy, days [median (IQR)]d 14 (11  20)
Time to active therapy, days [median (IQR)] 0 (0  1)
Length of stay, days [median (IQR)] 16 (9  33.5)
Therapeutic failure [n (%)]
At day 7 (primary outcome) 25 (8.2)
At day 30 (secondary outcome) 41 (13.4)
All-cause mortality [n (%)]
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At day 30 (secondary outcome) 9 (2.9)
BSI: bloodstream infection; CCI: age-adjusted Charlson comorbidity index; CI: 
confidence interval; CMV: cytomegalovirus; ICU: intensive care unit; IQR: 
interquartile range; mTOR; mammalian target of rapamycin; SD: standard 
deviation; TMP/SMX: trimethoprim-sulfamethoxazole.
a Data not available for 20 patients.
b Data not available for 13 patients.
c Data not available for 36 patients.
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731 TABLE 2. Description of therapeutic regimens administered.
Time interval from BSI onset
Therapeutic regimen [n (%)]
24 hours 72 hours 7 days
Active therapy 190 (62.1) 273 (89.2) 298 (97.4)
Monotherapy 179 (58.5) 261 (85.3) 287 (93.8)
Carbapenem 144 (47.1) 210 (68.6) 237 (77.5)
Meropenem 76 (24.8) 105 (34.3) 109 (35.6)
Ertapenem 46 (15.0) 72 (23.5) 94 (30.7)
Imipenem-cilastatin 22 (7.2) 33 (10.8) 32 (10.5)
BLBLI 22 (7.2) 33 (10.8) 32 (10.5)
Piperacillin-tazobactama 20 (6.5) 31 (10.1) 30 (9.8)
Amoxicillin-clavulanic acid 2 (0.7) 2 (0.7) 2 (0.7)
Quinolone 5 (1.6) 9 (2.9) 10 (3.3)
Aminoglycoside 3 (1.0) 3 (1.0) 1 (0.3)
Otherb 5 (1.6) 6 (2.0) 6 (2.0)
Combined therapy 10 (3.3) 12 (3.9) 11 (3.6)
Carbapenem-containing 7 (2.3) 9 (2.9) 9 (2.9)
Other combinationsc 3 (1.0) 3 (1.0) 2 (0.7)
Inactive therapy 116 (37.9) 33 (10.8) 8 (2.6)
Inactive agent in vitro 59 (19.3) 21 (6.8) 3 (1.0)
No antibiotic administered 57 (18.6) 12 (3.9) 5 (1.6)
BLBLI: β-lactam/β-lactamase inhibitor; BSI: bloodstream infection.
a Piperacillin-tazobactam was administered at the following doses: 4/0.5 g every 8 hours 
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hours (n = 2), 3/0.375 g every 6 hours (n = 2), 4/0.5 g every 24 hours (n = 1), unknown 
(n = 2).
b Other monotherapy regimens used within the first 24 hours included cefepime (n = 3), 
trimethoprim-sulfamethoxazole (n = 2), and tigecycline (n = 1).
c Other combination regimens used within the first 24 hours included BLBLI plus 
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TABLE 3. Univariate and multivariable analysis of factors for therapeutic failure at day 7 (primary outcome).
Univariatef MultivariablegTherapeutic 
failure at day 7
(n = 25)
No therapeutic 
failure at day 7
(n = 281)
OR 95% CI P-value OR 95% CI P-value
Age, years [mean ± SD] 57.2 ± 17.3 56.6 ± 13.7
Male gender [n (%)] 18 (72.0) 145 (51.6) 2.41 0.98  5.96 0.056
Time interval from transplantation, days [median (IQR)] 68 (23  194) 133 (36  1,543) 1.00 0.99 – 1.00 0.073
BSI within the first post-transplant month [n (%)] 7 (28.0) 64 (22.8)
Induction therapy with antithymocyte globulin [n (%)] 9 (36.0) 73 (26.0)
TMP/SMX prophylaxis within the prior month [n (%)] 18 (72.0) 145 (51.6) 2.41 0.98  5.96 0.056
Urinary stenosis [n (%)] 9 (36.0) 46 (16.4) 2.87 1.19  6.89 0.018 - - -
ICU admission within the prior month [n (%)] 6 (24.0) 31 (11.0)
Dialysis within the prior month [n (%)] 9 (36.0) 56 (19.9)
CMV infection within the prior month [n (%)] 5 (20.0) 26 (9.3)
CMV disease within the prior month [n (%)] 3 (12.0) 12 (4.3)
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Acute graft rejection within the prior month [n (%)] 6 (24.0) 24 (8.5) 3.38 1.23  9.27 0.018 - - -
Age-adjusted CCI [median (IQR)] 5 (3  6) 4 (2  6)
Rapidly or ultimately fatal McCabe scores [n (%)] 10 (40.0) 66 (23.5)
Pitt bacteremia score at BSI onset [median (IQR)] 2 (0  4.5) 0 (0  1) 1.50d 1.24  1.82 <0.0001 1.47d 1.21 – 1.77 <0.0001
Septic shock at BSI onset [n (%)]a 6 (24.0) 7 (2.6) 11.82e 3.61  38.69 <0.0001
Lymphocyte count ≤500 cells/μL at BSI onset [n (%)]b 14 (56.0) 103 (38.4)
Surgical debridement within the first 7 days [n (%)] 2 (8.0) 11 (3.9)
Non-surgical debridement [n (%)] 6 (24.0) 38 (13.5)
Removal/replacement of urinary catheter [n (%)] 7 (28.0) 60 (21.4)
Time to BSI source control [median (IQR)]c 9.5 (0.3  20) 2.5 (0  7)
Time to active therapy [median (IQR)] 0 (0  1) 0 (0  1)
Active therapy within the first 24 hours [n (%)] 15 (60.0) 175 (62.3)
Active therapy within the first 72 hours [n (%)] 23 (92.0) 250 (89.0)
BSI: bloodstream infection; CCI: age-adjusted Charlson comorbidity index; CI: confidence interval; CMV: cytomegalovirus; ESBL: extended spectrum beta-lactamase; ICU: intensive care 
unit; IQR: interquartile range; OR: odds ratio; SD: standard deviation; TMP/SMX: trimethoprim-sulfamethoxazole.
a Data not available for 12 patients.
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c Data not available for 36 patients.
d Hazard ratio estimated per one-point increase in the score.
e The variable “septic shock” was not entered into the model due to the existence of significant collinearity with the Pitt bacteremia score.
f Variables entered into the multivariable model are highlighted in bold characters.
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TABLE 4. Univariate and multivariable analysis of factors for therapeutic failure at day 30 (secondary outcome). 




failure at day 30
(n = 265)
OR 95% CI P-value OR 95% CI P-value
Age, years [mean ± SD] 60.4 ± 12.3 56.1 ± 14.1
Male gender [n (%)] 23 (56.1) 140 (52.8)
Time interval from transplantation, days [median 
(IQR)]
97 (51.5  1,688)
124 (35  1,366)
BSI within the first post-transplant month [n (%)] 7 (17.1) 64 (24.2)
Induction therapy with antithymocyte globulin [n (%)] 13 (31.7) 69 (26.0)
TMP/SMX prophylaxis within the prior month [n (%)] 27 (65.9) 136 (51.3)
Urinary stenosis [n (%)] 7 (17.1) 48 (18.1)
ICU admission within the prior month [n (%)] 7 (17.1) 30 (11.3)
Dialysis within the prior month [n (%)] 12 (29.3) 53 (20.0)
CMV infection within the prior month [n (%)] 7 (17.1) 24 (9.1)
CMV disease within the prior month [n (%)] 2 (4.9) 13 (4.9)
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Acute graft rejection within the prior month [n (%)] 7 (17.1) 23 (8.7)
Age-adjusted CCI [median (IQR)] 6 (4  7) 4 (2  6) 1.24d 1.08  1.43 0.003 1.25d 1.05  1.48 0.010
Rapidly or ultimately fatal McCabe scores [n (%)] 15 (36.6) 61 (23.0)
Pitt bacteremia score at BSI onset [median (IQR)] 1 (0  4) 0 (0  1) 1.62d 1.32  1.99 <0.0001 1.72d 1.35  2.17 <0.0001
Septic shock at BSI onset [n (%)]a 9 (24.3) 4 (1.6) 20.33e 5.88  70.31 <0.0001
Lymphocyte count ≤500 cells/μL at BSI onset [n (%)]b 24 (64.9) 93 (36.3) 3.24 1.57  6.66 0.001 3.16 1.42 – 7.06 0.005
Surgical debridement within the first 7 days [n (%)] 6 (14.6) 20 (7.5)
Non-surgical debridement [n (%)] 3 (7.3) 41 (15.5)
Removal/replacement of urinary catheter [n (%)] 8 (19.5) 59 (22.3)
Time to BSI source control [median (IQR)]c 1 (-1  9) 3 (0  9)
Time to active therapy [median (IQR)] 0 (0  1) 0 (0  1)
Active therapy within the first 24 hours [n (%)] 27 (65.9) 163 (61.5)
Active therapy within the first 72 hours [n (%)] 36 (87.8) 237 (89.4)
Active therapy within the first 7 days [n (%)] 41 (100.0) 257 (97.0)
BSI: bloodstream infection; CCI: age-adjusted Charlson comorbidity index; CI: confidence interval; CMV: cytomegalovirus; ESBL: extended spectrum beta-lactamase; ICU: intensive care 
unit; IQR: interquartile range; OR: odds ratio; SD: standard deviation; TMP/SMX: trimethoprim-sulfamethoxazole.
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b Data not available for 13 patients.
c Data not available for 36 patients.
d Hazard ratio estimated per one-point increase in the score.
e This variable was not entered into the model due to the existence of significant collinearity with the Pitt bacteremia score.
f Variables entered into the multivariable model are highlighted in bold characters.
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FIGURE LEGENDS
 Figure 1. Primary (therapeutic failure at day 7) (a) and secondary (therapeutic failure at day 30) (b) 
study outcomes according to the administration of active (versus inactive) therapeutic regimens or 
combination therapy (versus monotherapy) within the first 72 hours. BSI: bloodstream infection.
 Figure 2. Primary (therapeutic failure at day 7) (a) and secondary (therapeutic failure at day 30) (b) 
study outcomes according to the administration of a carbapenem-containing regimen (versus any 
other active therapy) or BLBLI-based (versus carbapenem-based) monotherapy within the first 72 
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Supplemental Material
 Table S1. Propensity score modelling: Comparison of baseline characteristics between patients 
receiving a carbapenem-containing regimen or any other active regimen within the first 72 hours 
from the onset of bloodstream infection.
 Table S2. Propensity score modelling: Comparison of baseline characteristics between patients 
receiving β-lactam/β-lactamase inhibitor- or carbapenem-based monotherapy during the first 72 
hours from the onset of bloodstream infection.
 Table S3. Length of hospital say according to different therapeutic regimens administered during the 
first 72 hours from the onset of bloodstream infection.
 Table S4. Sensitivity analysis: Effect on primary and secondary study outcomes of different 
therapeutic regimens administered within the first 24 hours and 7 days from the onset of 
bloodstream infection.
 Figure S1. Odds ratios (circles) with 95% confidence intervals (whiskers) for therapeutic failure at 7 
(a) and 30 days (b) according to the use of carbapenem-containing regimen (versus any other active 
therapy) during the first 72 hours from the onset of bloodstream infection.
 Figure S2. Odds ratios (circles) with 95% confidence intervals (whiskers) for therapeutic failure at 7 
(a) and 30 days (b) according to the use of carbapenem-based (versus β-lactam/β-lactamase 
inhibitor-based) monotherapy during the first 72 hours from the onset of bloodstream infection.
 Figure S3. Sensitivity analysis: Primary (therapeutic failure at day 7) (a) and secondary (therapeutic 
failure at day 30) (b) study outcomes according to the administration of active (versus inactive) 
therapeutic regimens or combination therapy (versus monotherapy) within the first 24 hours from 
the onset of bloodstream infection.
 Figure S4. Sensitivity analysis: Primary (therapeutic failure at day 7) (a) and secondary (therapeutic 
failure at day 30) (b) study outcomes according to the administration of a carbapenem-containing 
regimen (versus any other active therapy) or β-lactam/β-lactamase inhibitor-based (versus 
carbapenem-based) monotherapy within the first 24 hours from the onset of bloodstream infection.
 Figure S5. Sensitivity analysis: Secondary study outcome (therapeutic failure at day 30) according to 
the administration of (a) active (versus inactive) therapeutic regimens or combination therapy 
(versus monotherapy), or (b) carbapenem-containing regimen (versus any other active therapy) or β-
lactam/β-lactamase inhibitor-based (versus carbapenem-based) monotherapy within the first 7 days 
from the onset of bloodstream infection.A
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